ProQR Therapeutics N.V. (NASDAQ:PRQR - Free Report) - Research analysts at HC Wainwright cut their FY2026 earnings per share estimates for ProQR Therapeutics in a research report issued to clients and investors on Friday, November 13th. HC Wainwright analyst A. Ghosh now anticipates that the biopharmaceutical company will post earnings per share of ($0.44) for the year, down from their previous forecast of ($0.43). HC Wainwright currently has a "Buy" rating and a $8.00 target price on the stock. The consensus estimate for ProQR Therapeutics' current full-year earnings is ($0.45) per share. HC Wainwright also issued estimates for ProQR Therapeutics' Q1 2027 earnings at ($0.11) EPS, Q2 2027 earnings at ($0.11) EPS, Q3 2027 earnings at ($0.11) EPS, Q4 2027 earnings at ($0.11) EPS and FY2028 earnings at ($0.33) EPS.
A number of other equities analysts have also weighed in on the stock. Wall Street Zen upgraded shares of ProQR Therapeutics from a "strong sell" rating to a "hold" rating in a research report on Saturday, August 15th. Weiss Ratings restated a "sell (d-)" rating on shares of ProQR Therapeutics in a research report on Thursday. Chardan Capital restated a "buy" rating and set a $3.00 price objective on shares of ProQR Therapeutics in a research report on Thursday, October 1st. Raymond James Financial restated a "strong-buy" rating on shares of ProQR Therapeutics in a research note on Friday. Finally, Bank of America started coverage on shares of ProQR Therapeutics in a report on Thursday, August 20th. They issued a "buy" rating and a $8.00 target price for the company. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $7.60.
Read Our Latest Report on ProQR Therapeutics
ProQR Therapeutics Stock Performance
NASDAQ PRQR opened at $1.18 on Tuesday. ProQR Therapeutics has a 12 month low of $1.17 and a 12 month high of $2.48. The company's 50 day moving average is $1.56 and its two-hundred day moving average is $1.67.
ProQR Therapeutics (NASDAQ:PRQR - Get Free Report) last announced its quarterly earnings data on Thursday, November 12th. The biopharmaceutical company reported ($0.10) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.11) by $0.01. ProQR Therapeutics had a negative return on equity of 73.83% and a negative net margin of 223.51%. The company had revenue of $5.84 million during the quarter, compared to the consensus estimate of $4.30 million.
Institutional Inflows and Outflows
Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Marshall Wace LLP bought a new stake in shares of ProQR Therapeutics during the third quarter valued at approximately $1,860,000. Alpha Wealth Funds LLC bought a new position in shares of ProQR Therapeutics during the third quarter worth $41,000. RFG Advisory LLC boosted its position in shares of ProQR Therapeutics by 236.8% during the second quarter. RFG Advisory LLC now owns 64,000 shares of the biopharmaceutical company's stock worth $119,000 after acquiring an additional 45,000 shares during the last quarter. Axiom Investment Management LLC bought a new position in shares of ProQR Therapeutics during the first quarter worth $53,000. Finally, Bank of America Corp DE grew its stake in ProQR Therapeutics by 6.4% during the first quarter. Bank of America Corp DE now owns 185,110 shares of the biopharmaceutical company's stock valued at $300,000 after acquiring an additional 11,186 shares in the last quarter. 32.65% of the stock is currently owned by institutional investors.
ProQR Therapeutics Company Profile
(
Get Free Report)
ProQR Therapeutics N.V. is a biotechnology company developing RNA-based medicines for genetic diseases. Its research centers on Axiomer, a platform designed to make targeted changes to RNA using the body's naturally occurring editing machinery. Founded in 2012 and based in Leiden, the Netherlands, ProQR initially focused on RNA therapies for inherited retinal disorders, including Usher syndrome and Leber congenital amaurosis. The company later broadened its emphasis to RNA editing and continues to develop potential treatments for genetic conditions.
Read More

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider ProQR Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ProQR Therapeutics wasn't on the list.
While ProQR Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.
This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.